Clinical Trial Update: A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports on pharmacodynamics, safety, tolerability, and pharmacokinetics of MT-3995 in patients with diabetic nephropathy, with the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• MT-3995

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Diabetic Nephropathy | Phase 2 | Status: COMPLETED